EcoDrugPlus

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSMAUG00000021282
Gene Symbol: CHRNA3
3 Cross references
207 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSMAUG00000001465
Gene Symbol: CHRNA4
4 Cross references
204 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 7 Subunit

Ensembl ID : ENSMAUG00000005544
Gene Symbol: CHRNA7
3 Cross references
243 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSMAUG00000021538
Gene Symbol: CHRNB2
4 Cross references
197 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSMAUG00000012409
Gene Symbol: CHRNB4
4 Cross references
198 Possible Orthologues:

Chymase

Ensembl ID : ENSMAUG00000011423
Gene Symbol: LOC101842838
4 Cross references
292 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSMAUG00000010556
Gene Symbol: F2R
4 Cross references
327 Possible Orthologues:

Coagulation Factor Ii, Thrombin

Ensembl ID : ENSMAUG00000009414
Gene Symbol: F2
4 Cross references
85 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSMAUG00000009782
Gene Symbol: F3
3 Cross references
243 Possible Orthologues:

Coagulation Factor Vii

Ensembl ID : ENSMAUG00000010922
Gene Symbol: F7
4 Cross references
274 Possible Orthologues:

Coagulation Factor Xi

Ensembl ID : ENSMAUG00000010989
Gene Symbol: F11
4 Cross references
216 Possible Orthologues:

Coagulation Factor Xii

Ensembl ID : ENSMAUG00000011296
Gene Symbol: F12
3 Cross references
185 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).